Intraoperative Radiotherapy (IORT) for Rectal Cancer Using the Photon Radiosurgery System (PRS): A Phase I Clinical Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rectal Neoplasm
- Sponsor
- University of Dundee
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- surgical complication rate
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
The investigators would like to test the safety and efficacy of intraoperative radiotherapy (IORT) in rectal cancer using the Photon Radiosurgery System (PRS).
Detailed Description
Rectal cancer is usually managed by a combination of surgery and x-ray treatments (radiotherapy). The standard way of delivering radiotherapy is with external 'beams' directed at the tumour site. However, although in rectal cancer these treatments are effective, patients are often troubled by late side effects. An alternative option is to deliver the x-rays at the same time as surgery. This is known as intraoperative radiotherapy, or IORT, and a number of techniques have already been tried. There is a new IORT technology known as the Photon Radiosurgery System (PRS) which we are using to treat breast and brain cancers. Our experience to date has informed us that IORT with this x-ray source is safe and effective. We would like to use the technology to treat rectal cancer and believe that it may improve disease outcomes without the side effects associated with standard radiotherapy. We would also like to study the biological processes that follow radiation. It is not understood why some people are more sensitive to x-ray treatments than others. If we knew the reasons for this then we might be able to individualise treatments.
Investigators
Ian Sanders
Specialist Registrar
University of Dundee
Eligibility Criteria
Inclusion Criteria
- •Operable rectal cancer
Exclusion Criteria
- •Locally advanced disease requiring long course pre-operative chemoradiation, metastatic disease
Outcomes
Primary Outcomes
surgical complication rate
Time Frame: 30 days post treatment
Secondary Outcomes
- survival(5 year)
- local control(5 year)